Allurion Technologies Inc News - ALUR | Aktien New York Börse

Allurion Presents Data From Largest Ever Real-World Experience of 19,428 Patients at The Obesity Society’s Annual Conference

19,428 patients treated with the Allurion Program across 72 countries lost an average of 12.2% of total body weight Allurion Technologies, Inc...

Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024

Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it will...

Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon

Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the submission of the first three modules of its...

Allurion Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight Loss

In a study of 167 patients, average weight reduction was 15.7% at four months, 17.1% at six months, and 14.7% at one year Body fat percentage...

Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss

Systematic review of 11 studies involving 2,107 patients reports average weight reduction of 12.5% with significant improvements in metabolic...

Allurion Receives Continued Listing Standards Notice from NYSE

Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it received...

Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity

In a study of 91 adolescents, average weight loss was 13.1% at four months with no serious adverse events Allurion Technologies, Inc. (NYSE:...

Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors

Mr. Johns has worked over two decades bringing leading GLP-1 weight loss drugs and other metabolic drugs to market Allurion Technologies, Inc...

Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion Program

Average weight reduction in 486 patients improved from 10.5% at four months to 13.7% at one year on the Allurion Program Separate studies with...

Allurion Announces the Appointment of Adrian Wild as Senior Vice President, International Commercial

Mr. Wild brings over 20 years of experience building profitable commercial organizations at leading healthcare brands Allurion Technologies, Inc...

Allurion Receives Continued Listing Standards Notice from NYSE

Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it received...

Allurion Reports Second Quarter 2024 Financial Results and Provides Business Update

Results highlighted by strong sequential revenue growth and record procedure volume Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the...

Allurion suspend les ventes et retire l'approvisionnement du Ballon Allurion en France jusqu’à la mise en œuvre d'un plan de réduction des risques

Allurion Technologies, Inc. (NYSE: ALUR), une entreprise qui s’est donné pour objectif de combattre l’obésité, a annoncé aujourd'hui avoir...

Allurion to Report Second Quarter 2024 Financial Results on August 13, 2024

Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it will...

Allurion Announces Pricing of $20 million Public Offering and Concurrent Private Placement

Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced the pricing of an...

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Allurion Technologies Inc (ALUR)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

ALUR Nachrichten

Allurion Presents Data From Largest Ever Real-World Experience of 19,428 Patients at The Obesity Society’s Annual Conference

Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024

Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon

Allurion Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight Loss

Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss

Allurion Receives Continued Listing Standards Notice from NYSE

Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity

Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors

Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion Program

Allurion Announces the Appointment of Adrian Wild as Senior Vice President, International Commercial

Allurion Receives Continued Listing Standards Notice from NYSE

Allurion Reports Second Quarter 2024 Financial Results and Provides Business Update

Allurion suspend les ventes et retire l'approvisionnement du Ballon Allurion en France jusqu’à la mise en œuvre d'un plan de réduction des risques

Allurion to Report Second Quarter 2024 Financial Results on August 13, 2024

Allurion Announces Pricing of $20 million Public Offering and Concurrent Private Placement

ALUR Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Allurion Technologies Inc (ALUR) News

Allurion Technologies Inc (ALUR)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

ALUR Nachrichten

Allurion Presents Data From Largest Ever Real-World Experience of 19,428 Patients at The Obesity Society’s Annual Conference

Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024

Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon

Allurion Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight Loss

Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss

Allurion Receives Continued Listing Standards Notice from NYSE

Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity

Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors

Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion Program

Allurion Announces the Appointment of Adrian Wild as Senior Vice President, International Commercial

Allurion Receives Continued Listing Standards Notice from NYSE

Allurion Reports Second Quarter 2024 Financial Results and Provides Business Update

Allurion suspend les ventes et retire l'approvisionnement du Ballon Allurion en France jusqu’à la mise en œuvre d'un plan de réduction des risques

Allurion to Report Second Quarter 2024 Financial Results on August 13, 2024

Allurion Announces Pricing of $20 million Public Offering and Concurrent Private Placement

ALUR Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen